SWA
ALXN

Stratos Wealth Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Stratos Wealth Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,778
Closed -$272K – 256
2019
Q3 		$272K Buy
2,778
+314
+13% +$35.4K 0.1% 200
2019
Q2 		$323K Sell
2,464
-9
-0.4% -$1.16K 0.13% 164
2019
Q1 		$334K Buy
+2,473
New +$308K 0.18% 145

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stratos Wealth Advisors's ALXN Position: Q4 2019 in Review

Stratos Wealth Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 2,778 shares — an estimated $272K sold.

Stratos Wealth Advisors first reported a position in ALXN in Q1 2019 and held it in 3 quarters. The position peaked at $334K in Q1 2019. 667 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Stratos Wealth Advisors reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Stratos Wealth Advisors sold 2,778 Alexion Pharmaceuticals shares in Q4 2019, an estimated $272K.
  • Stratos Wealth Advisors first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Stratos Wealth Advisors's Alexion Pharmaceuticals position peaked at $334K in Q1 2019.
  • 667 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Stratos Wealth Advisors's 13F filing for Q4 2019, filed 29 Jan 2020.